First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
暂无分享,去创建一个
P. Ascierto | R. Dummer | M. Del Vecchio | M. Guida | J. Grob | R. Gutzmer | M. Maio | C. Lebbé | B. Dréno | E. Richtig | N. Meyer | P. Corrie | P. Ferrucci | M. Guidoboni | C. Dutriaux | M. Khattak | T. Meniawy | T. Lesimple | S. Mansard | K. Briscoe | M. Askelson | R. Herbst | J. Larkin | M. Lobo | Stéphane Dalle | Silvia Sabatini